StoryCommercial
Altos Labs acquires Dorian Therapeutics, entering senotherapeutics
Altos Labs acquired Dorian Therapeutics, a Stanford spinout developing senoblockers—small molecules targeting senescent cells. The deal broadens Altos' approach beyond partial reprogramming, adding complementary senotherapeutics with preclinical efficacy in lung fibrosis and osteoarthritis.
- Senoblockers modulate chromatin to neutralize or remove senescent cells while restoring repair functions.
- Lead candidates show preclinical efficacy in two major age-related diseases.
- Expands Altos' pipeline to include both reprogramming and senotherapeutics approaches.
- Dorian was founded by Maddalena Adorno (CEO) and Benedetta di Robilant (Chief Scientific Officer).
- Strengthens Altos' position in competitive biotech landscape.